Skip to main content
Premium Trial:

Request an Annual Quote

FDA Renews License to GVK Bio’s Biomarker Database

Premium

GVK Biosciences said this week that the US Food and Drug Administration has renewed its license to the Hyderabad, India-based firm's clinical biomarker database.

GVK Bio said that the FDA’s biomarker qualification group renewed its license to the GVK BIO Online Biomarker Database, or GOBIOM, database.

GOBIOM contains clinically evaluated, exploratory, and preclinical biomarkers associated with different therapeutic areas that have been reported in global clinical trials, clinical, and preclinical studies.

Specifically, the resource contains data related to about 20,000 biochemical, genomic, imaging, metabolite, cellular, and physiological biomarkers as well as experimental, analytical, clinical, and statistical information.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.